ESPERITE (ESP) postpones its next EGM to 30th April 2020 due to international sanitary risk and convenes its shareholders in Amsterdam to avoid unnecessary travel.
Esperite N.V. (Euronext: ESP) announces that it has postponed the Extraordinary General Meeting of Shareholders (EGM) originally scheduled on 26 March 2020 at 14:00 hours CET to 30th April 2020 at 14:00 hours CET, in order to avoid unnecessary travel risks.
Esperite invites its shareholders for the EGM at the
Hotel NH – Barbizon Palace, Prins Hendrikkade 59-72,
1012 AD Amsterdam
PDF Downloads – EGM 30 April 2020
Press Release : EGM-30-April-2020-Press-Release-SMF.pdf
Agenda : EGM-30-April-2020-Agenda.pdf
Notice : EGM-30-April-2020-Notice.pdf
Explanatory Notes : EGM-30-April-2020-Explanatory-Notes.pdf
Power of Attorney : EGM-30-April-2020-Power-of-Attorney.pdf
The EGM’s convocation notice, agenda and the explanatory notes to the agenda and further EGM materials have been updated can be downloaded from Esperite’s website.
Shareholders interested in attending the EGM are invited to contact Esperite: firstname.lastname@example.org
ESPERITE is a diversified investment company group specialized in Immunotherapy, Regenerative Medicine and Precision Medicine. Established in 2000, Esperite is a holding company, listed at Euronext Amsterdam and Paris. ESPERITE invests in companies able to transform the power of state-of-the-art technologies and scientific advancements into high quality products that bring the future of medicine to customers today at an affordable price.
ESPERITE provides early access to key information and knowledge, improving the way Science address human diseases and genetic disorders. ESPERITE attains the highest quality and ethical standards in the pursuit of its vision to bring the benefits of personalized medicine to society.
To learn more about the ESPERITE Group, or to book an interview with the CEO Frederic Amar: email@example.com or visit the websites at www.esperite.com